Hibiscus Products

Hibiscus Biopharma is a clinical-stage biotechnology company focused on the development of novel oncology therapeutics. Operating as a portfolio company of the venture studio Hibiscus BioVentures, the firm specializes in translating high-potential academic research into clinical assets. Its lead program, HBP-101, is a first-in-class small molecule inhibitor targeting the Hsp90/Cdc37 complex, which is essential for the stability and folding of numerous oncogenic client kinases. By disrupting this complex, Hibiscus Biopharma aims to provide a potent therapeutic option for patients with advanced solid tumors who have developed resistance to standard-of-care treatments.